A Phase 4 interventional study of MK0966; rofecoxib and Comparator: naproxen tablet 500 mg in Rheumatoid Arthritis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-25.
Sponsored by Merck Sharp & Dohme LLC · Phase 4, Interventional, and Treatment
A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 150 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Tender joint count
swollen joint count
patient's global assessment of disease activity
investigator's global assessment of disease activity
Patient pain assessment
patient's global assessment of response to therapy
investigator's global assessment of response to therapy
No study locations are listed for this record.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC